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A cDNA clone encoding guinea pig preproglucagon has been isolated from a pancreatic cDNA library. 
The predicted amino acid sequence of proglucagon is highly conserved in all regions, in comparison to other 
mammals, except for the C-terminal portion of the 29-residue glucagon region, in which 5 amino acid substi- 
tutions have occurred. These changes may serve to offset he reduced receptor-binding potency of the highly 
mutated insulin in this New World species. 
Glucagon EvoIution Hystricomorph 
1. INTRODUCTION 
Glucagon, the 29-residue pancreatic hormone 
that stimulates hepatic glycogenolysis and 
gluconeogenesis, is highly conserved in mammals 
[ 1,2]. It is derived from a 180-amino-acid precur- 
sor or preproglucagon, which bears an 
NHz-terminal signal sequence that is removed after 
membrane translocation [3,4]. Proglucagon in 
mammals is an 18 kDa (160 amino acid) protein 
consisting of an NHz-terminal propeptide (also 
called glicentin-related pancreatic peptide, GRPP), 
glucagon and two COOH-terminal glucagon-like 
peptides (GLP-1 and 2) separated by a short linker 
segment. Glucagon is synthesized in the islets of 
Langerhans, the stomach and intestine and 
possibly also in the brain [5-81. Different modes 
of processing of proglucagon have been observed 
[3]. Pancreatic islets release glucagon, GRPP and 
an intact COOH-terminal fragment containing 
both GLP-1 and GLP-2 [9], whereas the intestine 
releases a 69-amino-acid glucagon-containing 
polypeptide called glicentin which contains GRPP, 
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cDNA Glycogenolytic hormone 
glucagon and spacer peptide 1 [lo]. Mammals have 
a single preproglucagon gene. By contrast, the 
anglerfish has two non-allelic preproglucagon 
genes, the products of which are homologous to 
each other, but they lack the GLP-2 sequence pre- 
sent in the mammalian precursor [l 11. In addition, 
the NHz-terminal propeptide of the anglerfish pro- 
tein shows very low homology to its mammalian 
counterpart [l 11, however both glucagon and 
GLP-1 show a certain degree of homology to 
mammalian sequences. 
Hystricomorph rodents, such as the guinea pig, 
have evolved a number of divergent proteins under 
conditions of relative isolation in South America 
following the tertiary migration of the continent 
[12,13]. One such protein is insulin, which has ac- 
cumulated mutations in the A and B chains at the 
same frequency as in the signal sequence and in the 
C-peptide [14] suggesting that neutral mutations 
fixed by random drift may have allowed guinea pig 
insulin to acquire a new function which was fixed 
by positive selection. Guinea pig insulin has less 
metabolic activity than other mammalian insulins 
[15,16], but on the other hand has more growth- 
stimulating activity [ 171. Such an evolutionary 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/86/$3.50 @ 1986 Federation of European Biochemical Societies 25 
Volume 203, number 1 FEBS LETTERS July 1986 
change in insulin’s metabolic potency would seem 
likely to require compensatory changes in insulin 
counter-regulatory hormones, such as glucagon, as 
well as other hormones whose actions must be in- 
tegrated with that of insulin in metabolic regula- 
tion [14]. 
The first indication of the existence of an altered 
glucagon molecule in guinea pigs was a brief report 
by Sundby [ 181 indicating that its amino acid com- 
position was at variance with that of other mam- 
malian glucagons. On this basis, he postulated that 
guinea pig glucagon might be a larger peptide of 
approx. 40 residues. During the past year guinea 
pig glucagon has been isolated and sequenced by 
Conlon et al. [19] who observed that the COOH- 
terminal nonapeptide portion of glucagon has 5 
changes, compared to other mammals, while the 
sequence of the NHz-terminal portion was un- 
changed. No difference in the overall length of the 
molecule was found. They concluded that se- 
quence differences in the COOH-terminal part of 
guinea pig glucagon were an adaptive response to 
the lower metabolic activity of its divergent in- 
sulin. The COOH-terminal portion of glucagon is 
thought to be involved mainly in receptor binding 
while the NHz-terminal part is more directly in- 
volved in stimulation of adenylate cyclase [20]. 
More recent studies of Huang et al. [21] confirm 
these sequence changes in guinea pig glucagon and 
demonstrate that this molecule indeed has marked- 
ly reduced binding potency in both rat and guinea 
pig liver membranes. 
We have isolated a near full-length cDNA en- 
coding guinea pig preproglucagon. Its nucleotide 
sequence and predicted amino acid sequence are as 
similar to those of human as are the other mam- 
malian preproglucagons, in all regions except the 
COOH-terminal portion of glucagon. These obser- 
vations agree with the notion that selective 
pressure to maintain the structure and function of 
glucagon has been selectively suspended on the 
COOH-terminal portion of the molecule in order 
to restore a balanced metabolic hormonal status. 
2. MATERIALS AND METHODS 
2.1. Isolation and sequence of cDNA encoding 
guinea pig preproglucagon 
Poly(A)+ RNA was isolated from adult guinea 
pig (Cavia porcellus) pancreas as well as pancreatic 
26 
islets using standard procedures [22]. Double- 
stranded cDNA was prepared [23] and after 
methylation of internal EcoRI sites and the addi- 
tion of EcoRI linkers ligated into the EcoRI site of 
XgtlO [24]. Phage were packaged and recom- 
binants selected by plating on E. coli strain 
BNN102 [24]. Recombinants containing inserts en- 
coding guinea pig preproglucagon were identified 
in the islet cDNA library [l l] by cross- 
hybridization with a nick-translated insert from a 
Syrian hamster preproglucagon cDNA [3] under 
conditions of low stringency [washing in 0.2 x SSC 
(SSC = 0.15 M NaCl, 0.015 M sodium citrate), 
0.1% SDS, 42”C]. A partial fragment of the 
guinea pig preproglucagon cDNA was identified 
and then used to screen the library prepared from 
pancreatic RNA; cDNA inserts were cloned into 
Ml 3 mp19 and sequenced on both strands [25]. 
2.2. RNA blot analysis of guinea pig prepro- 
glucagon mRNA 
10 pg poly(A)+ RNA from guinea pig pancreas 
were denatured with glyoxal [26] and, after elec- 
trophoresis through a 1.2% agarose gel, transfer- 
red to a nitrocellulose filter [27]. ‘*P-labeled and 
glyoxal-denatured fragments of a Hind111 digest of 
hDNA and a HaeIII digest of 4X174 DNA were in- 
cluded as size standards. Nitrocellulose filter strips 
were hybridized with nick-translated guinea pig 
glucagon cDNA insert. 
3. RESULTS AND DISCUSSION 
cDNAs encoding guinea pig preproglucagon 
were isolated from libraries prepared with pan- 
creatic islet-enriched as well as pancreatic poly(A)+ 
RNA. A partial clone was isolated from the former 
and used to screen the pancreas cDNA library. The 
frequency of glucagon cDNA clones in this library 
was about one in 15000 phage. The nucleotide se- 
quence of one of these, gpGCG-2, contained an 
open reading frame of 540 base pairs (bp) which 
predicted the sequence of the 180-amino-acid 
guinea pig preproglucagon (fig.1). The 5’- and 
3 ‘-untranslated regions of this clone were 46 and 
467 bp, respectively. Guinea pig pancreatic 
preproglucagon mRNA is about 1350 bases (fig.2) 
suggesting that the 5 ‘-untranslated region of the 
mRNA may be 50-100 bases longer than indicated 
in fig. 1. Guinea pig preproglucagon has the typical 
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-20 Signal Peptide -10 
Met Lys Ser Val Tyr Phe Val Ala Gly Leu Phe Ile Met Leu Ala Gln Gly Ser 
GGTGCACCCGTTGCTAGCCACAGCCTACGAGCAGAAGGTAGCAAAA ATG AAG AGC GTT TAC TTT GTG GCT GGA TTG TTC ATA ATG CTA GCA CAA GGC AGC 
-1 Amino Terminal Peptide (GRPP) 10 20 
Trp Gln Arg Ser Leu Gln Asp Thr Glu Glu Lys Pro Arg Ser Val Ser Ala Ser Gln Thr Asp Met Leu Asp Asp Pro Asp Gln Met Asn 
TGG CAA CGT TCC CTT CAA GAC ACA GAA GAG AAA CCC AGA TCT GTC TCA GCC TCC CAA ACA GAC ATG CTT GAT GAT CCA GAT CAG ATG AAC 
30 Glucagon 40 50 
Glu Asp Lys Arg His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser Arg Arg Ala Gln Gln Phe Leu Lys Trp Leu 
GAA GAC AAG CGC CAT TCA CAG GGC ACA TTC ACC AGC GAC TAC AGC AAG TAC TTG GAT TCC AGG CGT GCT CAA CAA TTT TTti AAA TGG CTG 
60 Spacer Peptide 1 70 Glucagon-Like Peptide 1 80 
Leu Asn Val Lys Arg Asn Arg Asn Asn Ile Ala Lys Arg His Asp Glu Phe Glu Arg His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser 
TTG AAT GTC AAG AGG AAC AGG AAC AAC ATT GCC AAA CGT CAT GAT GAA TTT GAG AGA CAT GCT GAA GGG ACC TTT ACT AGT GAT GTA AGT 
90 100 110 Spacer Peptide 2 
Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly Arg Arg Asp Phe Pro Glu Glu Val Ala Ile 
TCT TAC TTG GAA GGC CAA GCT GCC AAG GAA TTC ATT GCT TGG CTG GTG AAA GGC CGA GGG AGG CGA GAC TTC CCA GAA GAA GTC GCC ATT 
120 Glucagon-Like Peptide 2 140 
Val Glu Glu Leu Gly Arg Arg His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn Leu Ala Thr Arg Asp Phe Ile 
GTG GAA GAA CTC GGC CGC AGA CAT GCC GAT GGC TCA TTC TCA GAT GAG ATG AAC ACT ATT CTT GAC AAT CTT GCC ACC AGA GAC TTT ATC 
150 160 
Asn Trp Leu Ile Gln Thr Lys Ile Thr Asp Arg Lys OC 
AAC TGG CTT ATT CAG ACC AAA ATC ACT GAC AGG AAG TAA GTATGTCACTCTTCAAGACCATCTTCACATCACCTGCCGTCCACTTGGAATGTTTGAAATTTTACAGTT 
CTGTAATTTTACAGAGTTGTACTCTCGAGTATTTCTTTGCAGGCTATTAAACATTTTTTAGCATTGTATAGCCAAATGATTATA~TGGAATAAACTATCGCCAGAATGTTGCTAAAATA 
TCAACTTTACAGTATAAAAGTCCTGTCTCTTGTTTTTATCTTATTTTGGTTGAAGTACCCCAACTTGTTTAAATTTAGCAGTGAAATTATTTTTCTATTATATACTTTGTAGATGTAAAT 
TAATCCAATCTGAAAATATCTGCATGCAATATCAGGAAAATGAAAACCTTGTA~CACAGCAGT~AACTGAAAAGAGAACTTCTTAAAGCCTTTTTCATAAAAATGCTCAGCTTTCAAT 
GTCTCAAAGATTGAATTAATAAATTTTCAAGCTTCAAAAAAAAAAAAAAAAAAAA (poly A) 
Fig. 1. Nucleotide sequence of guinea pig preproglucagon cDNA clone (gpGCG2) and the predicted amino acid sequence 
of protein. 
features of the mammalian precursor (fig.3), in- 
eluding signal peptide, NHz-terminal propeptide, 
glucagon, GLP-1 and -2, and the two shorter 
spacer peptides [ 10,281. 
Fig.2. Northern blot of guinea pig pancreatic 
preproglucagon mRNA. The size of mRNA is indicated. 
Comparison of the guinea pig and other mam- 
malian preproglucagon sequences, at both the pro- 
tein and nucleotide level, with the human sequence 
reveals that the various segments of the precursor 
have evolved at relative rates that roughly approx- 
imate evolutionary distances (table l), except for 
the COOH-terminal nine amino acids of glucagon 
(proglucagon 53-61, fig.3). Five amino acid 
substitutions have occurred in this region; two are 
relatively conservative and three represent signifi- 
cant changes in the properties of the amino acid 
side chains. These amino acid replacements 
predicted from the cDNA sequence agree with the 
sequences reported for guinea pig glucagon by 
Conlon et al. [ 191 and Huang et al. [21]. In con- 
trast, only 2 amino acid changes have been found 
in the duck [29] and alligator [30] glucagons. The 
other regions of the guinea pig proglucagon 
molecule show a very high degree of homology to 
the corresponding regions of other mammalian 
proglucagons. The striking sequence conservation 
in the region of GLP-1 and -2 implies an important 
but as yet undetermined physiological role for 
27 
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-20 Signal Peptlde -10 
"""la" net Lys Ser ,,e Tyr Phe va1 Ala Gly Le" Phe "a, wt Leu va, Gl" 
GQ"l"e ___ _-_ ___ I_??" _-- _-- --- --- _-_ --- ___ ___ ___ ___ _.- __- 
"*"l*teP _-- --- AS" --- --- ,,e --- --- --- Phe _-- -__ va, __* _-- ___ 
Rat _-- --_ ThP "a, --- ,,e --_ _-- --- --- ___ -__ ___ ___ ___ --- 
GP ___ --_ ___ "8, ___ ___ -__ --- ___ --- ___ ,,e ___ ___ A,4 __- 
-1 Aml"o Tern,"a, Peptzde (GRPP) IO 
Human Gly Ser Trp Gl" Arg SW Leu Gin Asp Thr G,u 61" Lys Ser Arg SW 
Go","e ___ _-_ ___ ___ ___ ___ --_ __- AS" --- __- -__ __- ___ Se? --- 
"**step --- --- --- -_- ",* ___ _*_ -_- __- --- __- -__ __- ___ *-- --- 
Rat ___ ___ ___ ___ "1~ A,a Ppp ___ ___ ___ ___ ___ As" A,a ___ __- 
GP --- --_ --- -__ ___ ___ ___ _-- ___ __- ___ -__ __- ppo --- --- 
20 
Human Phe 5er Ala SW Gln Ala Asp Pro Leu Se? Asp Pro Asp G," Met As" 
BD"r"e --- Pro --- Pro --- ,llr --- --- ___ G,y ___ ___ ___ ___ I,e --_ 
Hamster --- pro --- -.* --- Thr _-- --- _-- G," --- -_- --- __- ,le -"- 
Rat ___ pro ___ ___ ___ Th? G," ___ ___ G," ___ ___ ___ ___ ,le -__ 
GP "a, ___ ___ ___ ___ ,,,,. ___ "et ___ Asp ___ ___ __- ___ ___ ___ 
30 Glucagon 40 
Human G,u Asp Lyr Arg "1% 5er G," Gly Thr Phe Thr Ser Asp Tyr Ser Lyr 
G,)","e ___ --_ ___ ___ ___ .__ _._ _-- ___ --_ ___ ___ _-- ___ ___ __- 
Hamster ___ --_ ___ ___ ___ ___ -__ --- ___ --_ __- -__ __- ___ --- --_ 
Rat ___ __ __ __ __ __ __ _- ___ --_ ___ -__ _*- ___ --- _-- GP --- --_ __- ___ __ __ *__ __ ___ ___ ___ ___ ___ ___ ___ __- 
50 60 
Human Tyyr Le" Asp Ser Arg Ar9 Ala 6," Asp Phe "a, Gin Trp Leu ,,et As" 
B""f"e --- --_ --- _-- _*_ ___ ___ _-- ___ --_ ___ ___ ___ ___ .__ ___ 
“*mster ___ ___ ___ ___ ___ _*_ ___ __- ___ --_ ___ -__ __^ ___ _-_ _-- 
Rat ___ ___ ___ __* ___ ___ -__ _-- ___ --_ _-- -__ --- ___ --_ -_- 
GP ___ --_ __. ___ _-- ___ --- ___ G," ___ Leu Lys __- I_- Le" __- 
Spacer Peptide 1 70 Glucagon-Like 
Human Thr Lys Arg As" Ar9 Ar" Am ,,e Ala Lys Arg "1s Alp G," Phe Gl" 
GQ","e ___ --_ _-- ___ Ly$ __- --_ ___ ___ ___ ___ ___ ___ _*_ ___ ___ 
Hamster ___ -__ ___ ___ ___ _-_ ___ ___ *__ ___ ___ ___ ___ ___ ___ ___ 
Rat ___ ___ ___ ___ ___ ___ ___ -_- _-- --_ _-- -__ --- ___ --- .-- 
GP "a, -__ ___ ___ ___ ___ ___ --- --- --_ --- -__ --- __- ___ __- 
Peptrde 1 Go 90 
Human Arg His Ala Gl" G,y T,%r Phe Thr Ser Asp "a, Ser Set Tyr Leu Gl" 
Bovine --- 
“aisster *-- 
RX --- 
-_- 
-_* 
-__ 
___ ___ 
__- ___ 
___ ___ 
___ 
-__ 
___ 
___ -__ 
___ -_- 
___ ___ 
___ 
--_ 
_-- 
_-- 
___ 
___ 
--_ 
--_ 
_-- 
___ 
___ 
___ 
___ 
.__ 
___ 
___ 
__- 
__- 
__- 
___ __- 
___ __- 
___ __. 
GP ___ -__ ___ ___ __. ___ ___ _-- ___ --_ ___ ___ ___ ___ ___ ._- 
100 
Human Gly G," A,a Aila Ly% G," Phe Ile Ala Trp Lw Val Lys Gly Arg Gly 
fJo"lne ___ -__ ___ ___ __. __- -_- _-- --- --_ --- ___ --- _-- --- --- 
Ham$ter --- -_- --- __- --. ___ ___ _-- ___ --_ ___ ___ __- ___ .__ ___ 
Rat ___ ___ ___ ___ __. __- ___ _-- _-- --_ --- ___ --- _-- -__ --- 
GP ___ ___ ___ ___ ___ __* ___ ___ ___ --_ ___ ___ __- ___ _"_ _-_ 
spacer PeptIde 2 120 
Human Arg Arg ASP Phe PRO Glu Glu VI, Ala Ile Yal Glu Glu Leu Gly Arg 
go”,“e _.: __I ___ ___ __. ___ ___ __- As” ___ ___ ___ __- __- A@ -_- 
“*@Step ___ -__ ___ ___ ___ _*_ --- _-* It”- --- --- ___ __- ___ “__ -_- 
Rat ___ ___ ___ __* ___ ___ ___ _-- ___ --_ Ai* __- --- ___ ___ -_- 
GP ___ ___ ___ __^ ___ ___ ___ ___ ___ ___ __- ___ _-- ___ -_- _-- 
Glucag‘wLike Psptide 2 140 
"UlllZ" Are His Ala Aso Cl" SW Phe Ser AID Giu Ret AS" Thr Ile Leu ASP 
GP _-- -__ __- ___ ___ ___ .__ _-- ___ ___ ___ ___ ___ ___ ___ --_ 
150 
“ma” As" Leu Ala Ala Arg Asp Phe Ile As" Trp Leu ,,e G,n Thr Lys ,,e 
G"","e sep ___ ___ Thr _-_ ___ _-- --- --- --- --- Le" --. __- -__ --- 
itamster SW --- --- T,,r --- ___ .__ --- _-- -_- --- __- ___ ___ *__ --_ 
Rat ___ -__ __- Thr --_ _*" ___ _-- ___ -__ _-- ___ --_ --- __- --- 
GP ___ ___ ___ ,hr ___ ___ ___ --- _-- -__ --- __- --_ --- -_- --- 
160 
Human Thr Asp Arg LyS 
B"",ne ___ -__ __- ___ 
Hmster --- --- Lyr --- 
Rat --- ___ Lys --- 
pa ___ ___ ___ ___ 
Fig.3. Comparison of the amino acid sequences of 
human, bovine, Syrian hamster, rat and guinea pig 
preproglucans. The rat and bovine sequences are from 
[32] and [33], respectively. The corrected hamster [3] 
and human [2] sequences are from [lOl. 
these peptides. In contrast, the relatively rapid rate 
of mutation acceptance in the NHZ-terminal pro- 
peptide suggests that the structural requirements 
for its function (possibly in some aspect of 
gastrointestinal physiology, since it is part of 
glicentin, the major glucagon-containing molecule 
produced in the gut) are less stringent. Alternative- 
ly, the relative conservation in this region could 
reflect special structural requirements for folding 
or intracellular transport, as in the case of the C- 
peptide of proinsulin [3i]. The homology of the 
two anglerfish preproglucagons to the human 
precursor are included for comparison (table 1); 
the numerous substitutions occur relatively 
uniformly through both the glucagon and GLP-1 
sequences. The sequence of the 3 ‘-untranslated 
region of guinea pig preproglucagon mRNA is 
homologous (30-60~0) with this region of the 
other mammalian mRNAs although, except for the 
region following the polyadenylation signal, there 
is no large conserved region common to all mam- 
malian preproglucagon mRNAs. 
Our data demonstrate that mutations have ac- 
cumulated more rapidly in the region of the gene 
encoding the COOH-terminal region of guinea pig 
glucagon than in the rest of the preproglucagon 
molecule, which has been evolutionarily stable. 
These changes may have been required to maintain 
glucose homeostasis in response to the mutations 
in the insulin gene resulting in a metabolically less 
active insulin in this species [lS]. On the other 
hand, the lack of any changes within either GLP-1 
or -2 suggests that these peptides do not play a pro- 
minent role in glucose homeostasis, in keeping 
with evidence that these are not processed and 
released as such from islets [9], These alterations in 
glucagon have probably occurred in order to com- 
pensate for the lower biological activity of the 
guinea pig insulin. Their clustering in the COOH- 
terminal portion of the molecule provides strong 
support for the hypothesis that this region func- 
tions to enhance receptor-binding affinity [18,21]. 
Although it is possible that mutagenesis in the 
glucagon molecule may have preceded changes in 
the guinea pig insulin molecule this sequence of 
events seems less likely in view of the subordinate 
role of glucagon relative to that of insulin in 
regulating glucose homeostasis. Likewise it seems 
unlikely that the recently described substitutions in 
vasoactive intestinal polypeptide (VIP) in the 
guinea pig [34] are related in any direct functional 
sense to those in the insulin/glucagon axis de- 
scribed here. 
28 
Volume 203, number 1 FEBS LETTERS 
Table 1 
Comparison of nucleotide and amino acid sequence homology in domains of preproglucagon 
July 1986 
Signal peptide NHz-propeptide Glucagon l-20 Glucagon GLP-1 GLP-2 
21-29 
Nucleo- Amino Nucleo- Amino Nucleo- Amino Nucleo- Amino Nucleo- Amino 
tide acid tide acid tide acid Nucleo- Amino tide acid tide acid 
(or0 of (070 of (070 of (070 of (e/o of (To of tide acid (e/o of (To of (e/o of (@70 of
60) 20) 90) 30) 60) 20) (070 of (o/o of 111) 37) 99) 33) 
27) 9) 
Human/ 
guinea 
pig 88 85 83 83 92 100 67 44 96 100 89 97 
Human/ 
hamster 75 80 86 83 88 100 93 100 90 100 88 94 
Human/ 
rat 88 85 82 67 87 100 96 100 93 100 88 99 
Human/ 
bovine 97 95 83 77 93 100 93 100 99 100 87 88 
Human/ 
angler- 
fish I 48” 2ga 21” 17a 68 70 78 67 62 61 _ _ 
Human/ 
angler- 
fish II 52” 37= 14a 13a 65 75 78 78 67 71 - - 
a Gaps due to variations in length in these regions were scored as sequence differences 
All dibasic residues are excluded from the sequence comparisons, and the anglerfish I and II GLP-1 were compared 
to the COOH-terminal part of human GLP-1. The rat and bovine sequences were taken from [32] and [33], respectively 
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